Welcome to our dedicated page for Scynexis news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis stock.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company developing antifungal medicines based on its proprietary triterpenoid antifungal platform known as "fungerps." News about SCYNEXIS frequently centers on clinical data, regulatory interactions, collaborations, and its exclusive license agreement with GSK for ibrexafungerp, the active ingredient in the FDA-approved product BREXAFEMME for vulvovaginal candidiasis and reduction in the incidence of recurrent VVC.
On this page, readers can follow company announcements related to the development of next-generation fungerps, including SCY-247, which SCYNEXIS describes as a second-generation triterpenoid antifungal under clinical and preclinical evaluation for invasive fungal infections. Recent updates have highlighted positive Phase 1 single and multiple ascending dose results, preclinical data presented at scientific congresses, and plans for additional studies using both oral and intravenous formulations.
SCYNEXIS news also covers key events in its collaboration with GSK, such as the transfer of the BREXAFEMME New Drug Application, resolution of disagreements regarding the Phase 3 MARIO study in invasive candidiasis, and associated milestone or other payments. Regulatory and listing developments, including Nasdaq minimum bid price notices and extensions to regain compliance, are disclosed through company press releases and SEC filings.
Investors, clinicians, and researchers can use this news feed to review updates on clinical trial progress, antifungal data presentations, license agreement developments, and corporate milestones. Regularly checking this page helps users track how SCYNEXIS advances its fungerp platform, manages its partnership with GSK, and responds to regulatory and market requirements.
SCYNEXIS, Inc. announced positive results from its Phase 3 VANISH-306 study, published in the International Journal of Obstetrics and Gynaecology. Patients treated with oral ibrexafungerp showed significantly higher rates of clinical cure (63.3% vs. 44.0% placebo), mycological eradication (58.5% vs. 29.8% placebo), and clinical improvement (72.3% vs. 54.8% placebo) at Day-10. At a Day-25 follow-up, 73.9% of patients reported complete symptom resolution. Ibrexafungerp, FDA-approved in June 2021, is positioned as a groundbreaking treatment for vulvovaginal candidiasis, demonstrating safety and tolerability in clinical trials.
SCYNEXIS reported Q3 2021 results, highlighting BREXAFEMME sales of $0.5 million with 1,006 prescriptions, showing positive momentum into Q4. Insurance coverage for BREXAFEMME reached over 30% of commercially insured lives. The IV formulation of ibrexafungerp has progressed to clinical development after a successful Phase 1 trial. The company maintains a cash balance of $100 million, supporting operations into 2023. SCYNEXIS anticipates top-line data from the Phase 3 CANDLE study by early Q2 2022 and plans a supplemental NDA submission in Q2 2022.
SCYNEXIS, Inc. (NASDAQ: SCYX) recently completed a Phase 1 clinical study demonstrating the safety and tolerability of a liposomal IV formulation of ibrexafungerp. This double-blind, placebo-controlled trial involved 64 volunteers and confirmed that the formulation achieved target exposure without severe adverse events. Most reactions were mild and related to the infusion site. The company aims to utilize this formulation in diverse healthcare settings to combat severe fungal infections. Strategic options for optimizing development will be discussed soon.
SCYNEXIS, Inc. (NASDAQ: SCYX) has announced a conference call scheduled for November 10, 2021, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2021. The call will provide a corporate update on the company's pioneering efforts in developing innovative antifungal medicines, including the recently launched BREXAFEMME (ibrexafungerp), which was FDA-approved on June 1, 2021. Investors can access the live call via phone or webcast, with a replay available on the SCYNEXIS website for 90 days.
SCYNEXIS, Inc. (NASDAQ: SCYX) reported the publication of results from its Phase 3 VANISH-303 and Phase 2 DOVE studies for ibrexafungerp in the treatment of vulvovaginal candidiasis (VVC). In the VANISH-303 study, ibrexafungerp showed significant superiority over placebo in clinical cure rates (50.5% vs 28.6%) and mycological eradication (49.5% vs 19.4%). The DOVE study indicated that 300 mg BID for one day was optimal, with a clinical cure rate of 51.9%. These findings support the use of ibrexafungerp as a safe and effective treatment for VVC, providing new options for patients.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced the presentation of pooled data from its VANISH clinical development program at two medical meetings in October 2021. This data supports the efficacy and safety of BREXAFEMME™ (ibrexafungerp tablets) for treating vulvovaginal candidiasis. BREXAFEMME is the first new antifungal class approved since the 1990s, filling a significant gap in women’s healthcare. The presentations will occur at the NPWH Conference and ISIDOG Congress, highlighting the company's commitment to innovation in tackling difficult-to-treat infections.
SCYNEXIS, Inc. (NASDAQ: SCYX) reported promising preclinical data on ibrexafungerp's efficacy for treating mucormycosis, a rare and life-threatening fungal infection. The in vivo study demonstrated that ibrexafungerp monotherapy achieved survival rates similar to current standard therapies. When combined with amphotericin B, it significantly enhanced median and overall survival rates compared to monotherapy. The urgency for effective treatments is underscored by over 47,500 mucormycosis cases reported in India during the COVID-19 pandemic.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced that it will present interim data from its ongoing FURI and CARES studies on oral ibrexafungerp for refractory fungal infections at the 10th Trends in Medical Mycology meeting on October 8-11, 2021. In addition, pre-clinical data on ibrexafungerp for mucormycosis will be shared in an oral presentation. Ibrexafungerp is a novel antifungal agent, recently FDA-approved, showing promise against multidrug-resistant fungal infections. This ongoing clinical research aims to address an urgent need for effective oral treatments in hospitalized patients.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced promising interim results from the ongoing Phase 3 FURI study of ibrexafungerp, presented during IDWeek 2021. The analysis of 74 patients with severe fungal infections showed a 62.1% overall response rate, with notable efficacy in candidemia and intra-abdominal infections. The study highlights ibrexafungerp's potential for patients intolerant to standard treatments. The company continues to advance its position in the antifungal market, with emphasis on addressing drug-resistant infections.
SCYNEXIS, Inc. announced presentations of interim data from its Phase 3 FURI study at IDWeek 2021, focusing on ibrexafungerp for treating refractory fungal infections. The study includes 74 patients, highlighting outcomes for infections caused by Candida, especially drug-resistant strains. This is significant as invasive fungal infections are challenging to treat due to rising antifungal resistance. The company aims to make ibrexafungerp available to patients globally, following its FDA approval for BREXAFEMME in June 2021.